Studies on the pharmacology of the novel histamine H3 receptor agonist Sch 50971.
Experiments were performed to characterize the pharmacology of Sch 50971 ((+)-trans-4-(4(R)-methyl-3(R)-pyrolidinyl)-1H-imidazole dihydrochloride, CAS 167610-28-8), a novel histamine H3 receptor agonist. The activity of Sch 50971 was compared with that of (R)-alpha-methylhistamine (CAS 75614-87-8), a potent and moderately selective agonist of histamine H3 receptors, in a series of in vitro and in vivo assays. Sch 50971 is a high affinity, selective H3 receptor agonist in vitro and in vivo. Sch 50971 inhibits [3H]-N-alpha-methylhistamine (CAS 673-50-7) binding to the histamine H3 receptor in human brain (Ki = 5.0 nmol/l) and guinea pig brain (Ki = 2.5 nmol/l). Sch 50971 also inhibits electric field stimulated guinea pig ileum contractions (pD2 = 7.47) and decreases [3H]-norepinephrine (CAS 51-41-2) release (pD2 = 7.48) from guinea pig pulmonary artery by activation of presynaptic inhibitory H3 receptors. The in vitro effects of Sch 50971 are antagonized by low concentrations of a selective H3 antagonist, thioperamide (CAS 106243-16-7). Sch 50971 has low affinity (IC50's > 10 mumol/l) for histamine H1, dopamine D1 and D2, serotonin 5-HT2 and muscarinic cholinergic receptors. It also does not exhibit histamine H2-antagonist activity. In guinea pigs and cats, Sch 50971 exhibits in vivo H3 agonist activity. Sch 50971 inhibits sympathetic hypertension evoked by stimulation of the medulla oblongata in anesthetized guinea pigs (ED30 = 0.3 mg/kg i.v., ED30 = 1.0 mg/kg i.d.). Sch 50971 also inhibits the effects of sympathetic nerve stimulation on nasal resistance in cats. In these assays, Sch 50971 exhibits an efficacy and potency comparable to H3-agonist (R)-alpha-methylhistamine. However, under in vivo conditions, Sch 50971 does not exhibit histamine H1-mediated responses that are seen with (R)-alpha-methylhistamine at doses close to those that produce H3 effects. Therefore, Sch 50971 is a novel, potent and selective agonist of histamine H3 receptors with an improved in vitro and in vivo receptor profile selectivity compared with (R)-alpha-methylhistamine.
Hey
J A
JA
Allergy, Schering-Plough Research Institute, Kenilworth, New Jersey, USA.
Aslanian
R
R
Bolser
D C
DC
Chapman
R W
RW
Egan
R W
RW
Rizzo
C A
CA
Shih
N Y
NY
Fernandez
X
X
McLeod
R L
RL
West
R
R
Kreutner
W
W
D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D016275:Atrial Function; D001794:Blood Pressure / Q000187:drug effects; D001921:Brain / Q000378:metabolism; D016085:Bronchoconstrictor Agents / Q000494:pharmacology; D002415:Cats; D006168:Guinea Pigs; D006325:Heart Atria / Q000187:drug effects; D017442:Histamine Agonists / Q000493:pharmacokinetics / Q000494:pharmacology*; D006801:Humans; D007082:Ileum / Q000187:drug effects / Q000502:physiology; D007093:Imidazoles / Q000493:pharmacokinetics / Q000494:pharmacology*; D066298:In Vitro Techniques; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D009638:Norepinephrine / Q000378:metabolism; D011651:Pulmonary Artery / Q000187:drug effects / Q000378:metabolism; D011759:Pyrrolidines / Q000493:pharmacokinetics / Q000494:pharmacology*; D051381:Rats; D011954:Receptors, Dopamine / Q000378:metabolism; D011969:Receptors, Histamine H1 / Q000378:metabolism; D018100:Receptors, Histamine H3 / Q000378:metabolism; D011976:Receptors, Muscarinic / Q000378:metabolism; D011985:Receptors, Serotonin / Q000378:metabolism; D015656:Respiratory Mechanics / Q000187:drug effects
C115122:4-(4-methyl-3-pyrrolidinyl)-1H-imidazole dihydrochloride; D016085:Bronchoconstrictor Agents; D017442:Histamine Agonists; D007093:Imidazoles; D011759:Pyrrolidines; D011954:Receptors, Dopamine; D011969:Receptors, Histamine H1; D018100:Receptors, Histamine H3; D011976:Receptors, Muscarinic; D011985:Receptors, Serotonin; D009638:Norepinephrine